Pharma & Biotech Mergers & Acquisitions News
Biotechnology
California-based clinical-stage biotech Tempest Therapeutics has announced that the company plans to explore a full range of strategic alternatives to advance its promising clinical stage programs and maximize stockholder value. 10 April 2025
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Confirming recent rumors and speculation, Baxter International (NYSE:BAX ) said yesterday it has entered into a definitive agreement to acquire Gambro AB, a privately held dialysis product company based in Lund, Sweden, for total consideration of 26.5 billion Swedish kronor (around $4.0 billion). 4 December 2012
Pharmaceutical
US clinical-stage biopharma company focused on oncology and central nervous system (CNS) therapeutics Rexahn Pharmaceuticals (NYSE Amex: RNN) that Israel's Teva Pharmaceutical Industries (NYSE: TEVA) provide an additional funding to the firm. 28 November 2012
Pharmaceutical
In a second M&A deal this year, Israel's XTL Biopharmaceuticals (TASE: XTL) announced that it has acquired 4,620,356 shares, of Proteologics (TASE: PRTL) from Teva Pharmaceutical Industries for 6.5 million shekels ($1.7 million),, which represents an amount of 1.405 shekels per share (around 22% premium). 28 November 2012
Pharmaceutical
The world's largest chemical company, BASF (BAS: DE), plans to acquire Norway's Pronova BioPharma (OSE: PRON.OL), a pioneer in the field of research, development, and manufacturing of omega-3 fatty acids, in a deal valuing the company at 4.85 billion Norwegian kroner ($845 million). 22 November 2012
Pharmaceutical
Following swiftly on similar news from the US Food and Drug Administration, German drug major Bayer (BAYN: DE) has gained European Commission approval for its oral anticoagulant Xarelto (rivaroxaban) for the treatment of pulmonary embolism (PE) and the prevention of recurrent deep vein thrombosis (DVT) and PE in adults. This approval makes rivaroxaban the only novel oral anticoagulant approved in this indication in the European Union. 21 November 2012
Pharmaceutical
China's Hainan Haiyao Co has signed a letter of intent with Creator Investment and Good Catch Investments Limited, respectively for the acquisition of 250,564 common shares and 871,382 A preferred shares of SinoMab Bioscience, a Hong Kong-based company with offices and manufacturing facilities in Shenzhen. 19 November 2012
Pharmaceutical
US drug firm Allergan (NYSE: AGN), best known as the maker Botox (onabotulinumtoxinA) anti-wrinkle injections, has entered into a definitive agreement with SkinMedica to acquire the privately held company's topical aesthetics skin care business. Under the terms of the agreement, Allergan will pay SkinMedica $350 million up-front (subject to certain adjustments) for the business, which includes a variety of "physician dispensed" non-prescription aesthetic skin care products and prescription products. 18 November 2012
Pharmaceutical
In a move that looks set to thwart Germany-based Bayer's (BAYN: DE) plans to acquire the US nutritional products firm, consumer products conglomerate Reckitt Benckiser (LSE: RBL) last night launched a counter bid to acquire Schiff Nutrition International (NYSE: SHF). Bayer, which announced its $34 per share ($1.2 billion) takeover offer last month (The Pharma Letter October 30), told TPL this morning that it could not comment on the situation at this stage. 16 November 2012
Pharmaceutical
US cancer and autoimmune diseases drug developer Myrexis (Nasdaq: MYRX) said on Friday that its board of directors has determined, after extensive and careful consideration of potential strategic alternatives, that it is in the best interests of the company and its shareholders to dissolve the firm and liquidate its assets. 12 November 2012
Pharmaceutical
India's Sun Pharmaceutical Industries (SUN.BO) has entered into a definitive agreement to acquire US dermatological company DUSA Pharmaceuticals (Nasdaq: DUSA), which is focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform. 9 November 2012
Pharmaceutical
Privately-held Israeli company Immune Pharmaceuticals and US drug developer EpiCept Corp (Nasdaq: EPCT) yesterday announced that they have entered into a definitive merger agreement. The transaction is anticipated to close during the first quarter of 2013 and is subject to satisfaction of certain customary closing conditions, including the approval of a majority of EpiCept shareholders. 8 November 2012
Pharmaceutical
Otsuka Pharmaceutical (TYO: 4768), a mid-size Japanese drugmaker, and Abdi brahim have established a joint venture in Turkey, to be called Abdi Ibrahim Otsuka Pharmaceutical AS, with 50% of investment each from the two partners. 7 November 2012
Pharmaceutical
Takeda Pharmaceutical (TYO: 4502), Japan's largest drugmaker, has clearly not quenched its thirst for acquisitions, as it announced yesterday an agreement to buy privately-held US firm Envoy Therapeutics, via its USA-based subsidiary Takeda America Holdings. 7 November 2012
Pharmaceutical
French drug discovery and development firm Exonhit Therapeutics (ALEHT:FP) has entered into an agreement to acquire 100% of InGen BioSciences from its founders and financial shareholders, IPSA (ex-Innoven Partenaires) and funds managed by Amundi Private Equity Funds. 7 November 2012
Pharmaceutical
USA-based Charles River Laboratories International (NYSE:CRL) has entered into an agreement to acquire 75% ownership of Vital River, a leading commercial provider of research models and related services in China, for around $27 million, subject to certain closing adjustments. 31 October 2012
Pharmaceutical
US health care firm Allergan (NYSE: AGN) revealed yesterday that revenues for its fiscal fourth-quarter ended September 30, 2012, rose 6% to $1.41 billion, undershooting analysts' estimates of $1.43 billion. 31 October 2012
Pharmaceutical
UK pharma giant GlaxoSmithKline (LSE: GSK) says that Healthcare, its HIV/AIDS joint venture with Pfizer, and Japanese drug major Shionogi (TYO: 4507) have revised their joint venture partnership for the development of integrase inhibitors, effective 31 October, 2012. 30 October 2012
Pharmaceutical
MicuRx Pharmaceuticals, a privately-held US biopharmaceutical company developing next-generation antibiotics, and China-based Shanghai ZhangJiang Biomedical Industry Venture Capital yesterday announced the establishment of Shanghai MengKe Pharmaceuticals, a joint venture formed to fund the development and commercialization of MRX-I for the Chinese market. 24 October 2012
Pharmaceutical
USA drugmaker BioCryst Pharmaceuticals (Nasdaq: BCRX) has signed a definitive accord to acquire privately held Presidio Pharmaceuticals in an all-stock transaction that values the latter at around $101 million. The transaction is expected to close in the first quarter of 2013, and is subject to customary conditions, including approval by BioCryst shareholders. 22 October 2012
Pharmaceutical
Italian drugmaker Recordati (RC: MI) yesterday announced the signature of the agreements covering the acquisition of all rights to five product lines on the Russian and Commonwealth of Independent States (CIS) market: Alfavit, Qudesan, Vetoron, Focus and Carnitone. 16 October 2012
Pharmaceutical
US biotech start-up RayThera has secured $110 million in series A financing to fund the early clinical development of its small molecule drug candidates in immunology. 8 April 2025
Pharmaceutical
US private equity firm Vance Street Capital has expanded its life sciences manufacturing platform with the acquisition of Irish contract manufacturer Zenith Adhesive Components, adding further technical capabilities and boosting regional reach. 4 April 2025
Pharmaceutical
Plenty of money changed hands in pharma M&A during March, with the biggest deal a $6.7 billion merger between Mallinckrodt Pharmaceuticals and Endo, after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis. 2 April 2025
Pharmaceutical
Japanese drugmaker Sumitomo Pharma said yesterday that it is divesting its Asian business to major Japanese trading house Marubeni for roughly 72 billion yen ($480 million) in a deal that forms part of its post-Latuda (lurasidone) turnaround efforts. 2 April 2025
Pharmaceutical
Florida-based MIRA Pharmaceuticals, a pharma company developing therapeutics for neurologic and neuropsychiatric disorders, has signed a binding letter of intent (LOI) to acquire privately held Delaware firm SKNY Pharmaceuticals. 24 March 2025
Pharmaceutical
Privately-held drugmaker Paratek Pharmaceuticals is to buy specialty pharma Optinose, including its approved product Xhance (fluticasone propionate). 20 March 2025
Pharmaceutical
Chinese pharmaceutical company Fosun Pharmaceutical Group has agreed to sell its stake in private hospital operator United Family Healthcare to an investment firm owned by US private equity giant Warburg Pincus. 14 March 2025
Pharmaceutical
USA-based Azurity Pharmaceuticals says it has completed its acquisition of Covis Group from existing investors and the privately-held Swiss drugmaker is now a wholly-owned subsidiary of Azurity. 14 March 2025
Pharmaceutical
Ireland-based Mallinckrodt Pharmaceuticals and Endo Inc have agreed to combine in a stock and cash deal worth $6.7 billion, after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis. 13 March 2025
Pharmaceutical
Alliance Pharma has accepted a final increased cash offer from investment firm DBAY Advisors, valuing the UK-based pharmaceutical company at approximately £362 million ($468 million). 11 March 2025
Pharmaceutical
USA-based Endo Inc today announced it has entered into a definitive agreement to divest its international pharmaceuticals business, primarily operated through Canada-based specialty pharmaceutical company Paladin Pharma to Knight Therapeutics. 11 March 2025
Pharmaceutical
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and AstraZeneca. US pharma major AbbVie became the latest entrant to the weight management sector, striking a deal with Gubra for its obesity candidate GUB14295. On the M&A front, Ireland-headquartered Jazz Pharmaceuticals announced it is acquiring Chimerix for around $935 million to expand its oncology portfolio. USA-based scPharmaceuticals gained US Food and Administration (FDA) approval for its supplemental new drug application (sNDA) for Furoscix in chronic kidney disease (CKD). 9 March 2025
Pharmaceutical
Private equity firms acquiring assets were among the most eye-catching deals in pharma M&A during February. 6 March 2025
Pharmaceutical
Ireland-headquartered Jazz Pharmaceuticals has entered into a definitive agreement to acquire US biopharma company Chimerix for $8.55 per share in cash, representing a total consideration of around $935 million. The news sent Chimerix’ shares rocketing almost 70% to $8.40. 5 March 2025
Pharmaceutical
French biotech start-up studio Argobio and non-profit biomedical research center the Institut Pasteur have announced the launch of Enodia Therapeutics. 26 February 2025
Pharmaceutical
Kelso Pharma, the British specialty pharma business backed by Apposite Capital, today announced the acquisition of the UK pharma business, Alturix Holdings Limited. Financial terms were not disclosed. 24 February 2025
Pharmaceutical
US drugmaker Cosette Pharmaceuticals has entered into a definitive agreement to acquire all the outstanding shares of Australia-based Mayne Pharma with the aim of expanding its health portfolio. 21 February 2025
Pharmaceutical
FibroGen today announced the sale of its China subsidiary to UK pharma major AstraZeneca for around $160 million, with the news sending the California-based company’s shares soaring 27% to $0.71. 20 February 2025
Pharmaceutical
An Expert View from Nick Petschek, EMEA managing director at global change management firm Kotter International. 12 February 2025
Pharmaceutical
Caymen Islands-headquartered specialty drug firm Legacy Pharma has announced the completion of the acquisition of InterMune, along with the intellectual property rights to Esbriet (pirfenidone) in the USA, from Genentech, a subsidiary of Swiss pharma giant Roche. 11 February 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze